GLP-1 drugs have transformed the treatment of type 2 diabetes and obesity, helping people manage blood sugar levels, lose weight and improve several aspects of metabolic health.
The research, published in The Lancet Regional Health – Europe and widely reported in early November 2026, analysed real-world data from more than 80,000 patients and raises important questions about the consequences of stopping these widely prescribed medicines.